Attractive Call to Action Text
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus.
Advancing cancer research through multidisciplinary science, precision oncology, molecular diagnostics, immuno-oncology and innovative translational approaches.
Our research programme focuses on understanding the biological basis of cancer and translating scientific discoveries into clinically relevant applications.
Our ongoing translational research programmes address emerging areas of cancer biology, precision medicine, diagnostics and therapeutic innovation.
Selected projects focusing on cancer diagnosis, biomarkers, treatment response, genomics, immunology and innovative technologies.
Markers for Pathological Complete Response (PCR) in Triple Negative Breast Cancer (TNBC) using Spatial Biology.
Molecular mechanisms driving tumor heterogeneity in GI tract malignancies.
Hyperthermia as a potent radiosensitizer, chemosensitizer, and immunomodulator for HNCs.
Genomic and Immunophenotypic Landscape of B- and T-Cell Lymphomas in an Indian Cohort.
Impact of Tumor Hypoxia on Cytotoxic T-Lymphocyte Differentiation and Function in Tongue Squamous Cell Carcinoma.
Radiogenomic Markers for Glioma and Breast Cancer.
Early-stage cervical cancer diagnosis based on a novel Point-of-Care (POC) device.
Early detection of Triple Negative Breast Cancer (TNBC) by an Electrochemical Biosensor.
Molecular MRD Detection in Acute Leukemia (ALL and AML).
Predictive Biomarkers for HPV-Associated Cervical Transformation.
Extramural research grants received during the past five years.
| S. No. | Grant Title | Year | Name of Grantor | Status |
|---|---|---|---|---|
| 1 | Multimodal AI for Cancer Diagnosis and Treatment Using Radiology and Pathology | 2026 | ANRF-AISE | Ongoing |
| 2 | OncoWave: Precision Deep Hyperthermia Oncology Device for Head and Neck Cancers (HNCs) - A potent radiosensitizer, chemosensitizer, and immunomodulator for HNCs | 2026 | ANRF | Ongoing |
| 3 | Centre for Radiogenomics Research in Oncology for Theranostics Advancements | 2026 | ICMR | Ongoing |
Selected publications received during the past five years.
Surendran HP, Gopisetty G, Rajappa SJ, Rao TS, Unnikrishnan MK. Efficacy, safety, and characteristics of adoptive tumor-infiltrating lymphocyte therapy in solid tumours: a systematic review and meta-analysis. Front Oncol. 2026;16:1859306. doi:10.3389/fonc.2026.1859306
Pasha A, Velingkar A, Sharma R, et al. Diffuse large B-cell lymphoma: from molecular stratification to precision immunotherapy. Cells. 2026;15(13):1188. doi:10.3390/cells15131188
Othayoth R, Sarkar O. Nanoparticle-based precision modeling of primary and three-dimensional cell culture in cancer theranostics. Oncol Transl Med. Published online 2026. doi:10.1097/ot9.0000000000000151
Dontiboina HK, Gopisetty G, Arunachalam K. Pilot study on microwave preclinical system for targeted delivery of fractionated hyperthermia in murine solid tumors. Sci Rep. 2026;16:62731. doi:10.1038/s41598-026-62731-9
Heavican-Foral TB, Li Y, Lone W, et al. Tet2 deficiency alters CD4+ T cell function and promotes T cell lymphoma with a TFH cell immunophenotype. J Exp Med. 2026;223(6):e20250194. doi:10.1084/jem.20250194
Sharma R, Kudithipudi J, Singh H, Prabhu D, Vuree S. In silico identification of deleterious NT5C2 and PRPS1 mutations driving thiopurine resistance in relapsed acute lymphoblastic leukemia. Cancer Genet. 2026;302-303:8-12. doi:10.1016/j.cancergen.2026.01.001
Gadicherla R, Niraj N, Kamma S, Othayoth R. Characterization of mitochondrial DNA mutations in colorectal cancer progression by in-silico approach and use as potential biomarkers for diagnosis and prognosis. Egypt J Med Hum Genet. 2024;25(1):126. doi:10.1186/s43042-024-00599-y
Arora S, Sheoran S, Govindaiah P, Vure S. Hesperidin's role in the treatment of lung cancer: in-silico and in-vitro findings. In Silico Pharmacol. 2024;12(2):104. doi:10.1007/s40203-024-00265-6
Gadicherla R, Kamma S, Othayoth R. Exploring the impact of mitochondrial tRNA mutations on colorectal cancer development and their potential as biomarkers. Afr J Biol Sci. 2024;6(5):2528-2538.
Othayoth R, Khatri K, Gadicherla R, Kodandapani S, Botlagunta M. Multivitamin-cisplatin encapsulated chitosan nanoparticles modulate DDX3X expression in cancer cell lines. Nano Biomed Eng. 2023;15(1):1-12. doi:10.26599/NBE.2023.9290008
Botlagunta M, Khatri K, Madhavi L. Differential expression of DDX3 and microRNAs in response to hormone and cisplatin against cervical cancer. Eurasian J Med Oncol. 2023;6(4). doi:10.14744/ejmo.2023.96531
Annapurna SD, Pasumarthi D, Pasha A, et al. Identification of differentially expressed genes in cervical cancer patients by comparative transcriptome analysis. BioMed Res Int. 2021;2021:8810074. doi:10.1155/2021/8810074
Raghunath K, Sumathi C, Rajappa SJ, et al. Impact of naturopathy, yoga, and dietary interventions as adjuvant chemotherapy in the management of stage II and III adenocarcinoma of the colon. Int J Colorectal Dis. 2020;35(12):2309-2322. doi:10.1007/s00384-020-03711-x
Our research programmes bring together expertise in cancer biology, genomics, computational biology, spatial biology, immunology, diagnostics and translational medicine to advance cancer research and patient-focused innovation.
IACRF is committed to translating scientific discoveries into innovative approaches for cancer diagnosis, treatment and prevention.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus.